Superficial bladder cancer

Current Treatment Options in Oncology

Volumn 3, Issue 5, 2002, Pages 403-411

  Lamm, Donald L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bladder Cancer; Contraindication Hypersensitivity; Main Drug Interaction; Superficial Bladder Cancer; Thiotepa

Indexed keywords

BLADDER TUMOR; HUMAN; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; RECURRENT DISEASE; REVIEW; TIME;

COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; RECURRENCE; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0036781975     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-002-0005-4     Document Type: Article

References (20)

1. Dalbagni G, Genega E, Hashibe M, et al.: Cystectomy for bladder cancer: a contemporary series. J Urol 2001, 165:1111–1116. DOI: 10.1016/S0022-5347(05)66440-3
2. Lamm DL, Griffith JG: Intravesical therapy: does it affect the natural history of superficial bladder cancer? Semin Urol 1992, 10: 39–44.
3. Heney NM: Natural history of superficial bladder cancer: prognostic features and long-term disease course. Urol Clin North Am 1992, 19:429–433.
4. Vicente J, Laguna MP, Duarte D, Algaba F, Chechile G: Carcinoma in situ as a prognostic factor for G3pT1 bladder tumours. Br J Urol 1991, 68:380–382.
5. Bostwick DG: Natural history of early bladder cancer. J Cell Biochem 1992, 161:31–38. DOI: 10.1002/jcb.240501307
6. Fleshner N, Moadel A, Herr H, et al.: Influence of smoking status on outcomes in patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer 1999, 86:2337–2345. DOI: 10.1002/(SICI)1097-0142(19991201)86:11<2337::AID-CNCR23>3.0.CO;2-6
7. Byar D, Blackard D: Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 1977, 10: 556–561. DOI: 10.1016/0090-4295(77)90101-7
8. Kamat AM, Lamm DL: Chemoprevention of urological cancer [comment]. J Urol 2000, 163:1260.
9. Lamm DL, Riggs DR, Shriver JS, et al.: Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994, 151:21–26.
10. Pawinski A, Sylvester R, Kurth KH, et al.: A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 1996, 156:1934–1940. DOI: 10.1016/S0022-5347(01)65396-5
11. Friedman D, Mooppan UM, Rosen Y, Kim H: The effect of intravesical instillations of thiotepa, mitomycin C, and adriamycin on normal urothelium: an experimental study in rats. J Urol 1991, 145:1060–1063.
12. Salonia A, Lev A, Da Pozzo LF, et al.: Effect of local hyperthermia of the bladder on mitomycin C pharma-cokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 2001, 52:273–278. DOI: 10.1046/j.0306-5251.2001.01449.x
13. Lamm DL, Blumenstein BA, Crissman JD, et al.: Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000, 163:1124–1129. DOI: 10.1016/S0022-5347(05)67707-5
14. Belldegrun AS, Franklin JR, O’Donnell MA, et al.: Superficial bladder cancer: the role of interferon-alpha. J Urol 1998, 159:1793–1801. DOI: 10.1016/S0022-5347(01)63160-4
15. Flamm J, Bucher A: Adjuvant topical chemotherapy versus immunotherapy in primary superficial transitional cell carcinoma of the bladder. Br J Urol 1991, 67:70–73. DOI: 10.1111/j.1464-410X.1991.tb15072.x
16. O’Donnell MA, Krohn J, DeWolf WC: Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guérin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guérin alone previously failed. J Urol 2001, 166:1300–1304. DOI: 10.1016/S0022-5347(05)65757-6
17. Zietman AL, Grocela J, Zehr E, et al.: Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 2001, 58:380–385. DOI: 10.1016/S0090-4295(01)01219-5
18. Rodel C, Dunst J, Grabenbauer GG, et al.: Radiotherapy is an effective treatment for high-risk T1 bladder cancer. Strahlenther Onkol 2001, 177:82–88. DOI: 10.1007/PL00002387
19. Studer UE, Gerber E, Zimmermann A, et al.: Late results in patients treated with pi-mesons for bladder cancer [comment]. Cancer 1993, 72:439–447. DOI: 10.1002/1097-0142(19930115)71:2<439::AID-CNCR2820710226>3.0.CO;2-Z
20. Lamm DL: Intravesicle maintenance BCG immunotherapy in grade 3 stage T1 bladder cancer. Urology; In press.